CR20250413A - Compuestos de pirido[4,3–d]pirimidina - Google Patents

Compuestos de pirido[4,3–d]pirimidina

Info

Publication number
CR20250413A
CR20250413A CR20250413A CR20250413A CR20250413A CR 20250413 A CR20250413 A CR 20250413A CR 20250413 A CR20250413 A CR 20250413A CR 20250413 A CR20250413 A CR 20250413A CR 20250413 A CR20250413 A CR 20250413A
Authority
CR
Costa Rica
Prior art keywords
pyrido
pyrimidine compounds
processes
compounds
disorders
Prior art date
Application number
CR20250413A
Other languages
English (en)
Inventor
Alexander Burtea
Shouliang Yang
Asako Nagata
Scott Channing Sutton
Jillian Elyse Spangler
Benjamin Joseph Burke
Hanna Maria Wisniewska
Jacob Cole Deforest
Simon Paul Planken
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20250413A publication Critical patent/CR20250413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere un compuesto de Fórmula (I)–(III) y sales farmacéuticamente aceptables de los mismos para usar en medicina; a composiciones que los contienen; a procesos para su preparación; y a intermediarios usados en dichos procesos. Los compuestos la presente invención pueden ser útiles en el tratamiento, la prevención, la supresión y la mejora de enfermedades, trastornos y afecciones tales como el cáncer.
CR20250413A 2023-04-05 2024-04-02 Compuestos de pirido[4,3–d]pirimidina CR20250413A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202363494346P 2023-04-05 2023-04-05
US202363507621P 2023-06-12 2023-06-12
US202363540044P 2023-09-22 2023-09-22
US202363598907P 2023-11-14 2023-11-14
US202463550564P 2024-02-06 2024-02-06
US202463568399P 2024-03-21 2024-03-21
PCT/IB2024/053182 WO2024209339A1 (en) 2023-04-05 2024-04-02 Pyrido[4,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
CR20250413A true CR20250413A (es) 2025-11-06

Family

ID=90720860

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250413A CR20250413A (es) 2023-04-05 2024-04-02 Compuestos de pirido[4,3–d]pirimidina

Country Status (15)

Country Link
US (2) US20240336631A1 (es)
EP (1) EP4688788A1 (es)
JP (1) JP2026515630A (es)
KR (1) KR20250165440A (es)
CN (1) CN121079303A (es)
AU (1) AU2024253142A1 (es)
CL (1) CL2025002925A1 (es)
CO (1) CO2025013480A2 (es)
CR (1) CR20250413A (es)
DO (1) DOP2025000250A (es)
IL (1) IL323521A (es)
MX (1) MX2025011899A (es)
PE (1) PE20252775A1 (es)
TW (1) TW202504615A (es)
WO (1) WO2024209339A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向ｋｒａｓ之共價誘導之藥物結合物
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026078529A1 (en) * 2024-10-09 2026-04-16 Pfizer Inc. Solid and deuterated forms of pyrido[4,3-d]pyrimidine compounds
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
US11589667B2 (en) 2016-11-16 2023-02-28 Wink Robotics Deformable end effectors for cosmetic robotics
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
BR112023024906A2 (pt) * 2021-05-28 2024-02-15 Redx Pharma Plc Compostos
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途
MA71388A (fr) * 2022-07-05 2025-04-30 Pfizer Inc. Composés pyrido[4,3-d]pyrimidines
KR20250034087A (ko) 2022-07-09 2025-03-10 블로썸힐 테라퓨틱스, 인크. 질병 치료를 위한 융합 고리 kras 억제제
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024032704A1 (en) 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041573A1 (en) 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof

Also Published As

Publication number Publication date
KR20250165440A (ko) 2025-11-25
CN121079303A (zh) 2025-12-05
DOP2025000250A (es) 2025-11-30
CL2025002925A1 (es) 2026-01-23
TW202504615A (zh) 2025-02-01
EP4688788A1 (en) 2026-02-11
US12281127B2 (en) 2025-04-22
JP2026515630A (ja) 2026-05-19
CO2025013480A2 (es) 2025-10-09
IL323521A (en) 2025-11-01
US20240336631A1 (en) 2024-10-10
AU2024253142A1 (en) 2025-10-16
PE20252775A1 (es) 2025-12-22
WO2024209339A1 (en) 2024-10-10
US20250034173A1 (en) 2025-01-30
MX2025011899A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
DOP2025000250A (es) Compuestos de pirido[4,3-d]pirimidina
DOP2024000275A (es) Compuestos de pirido[4,3-d]pirimidina
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
CL2024003450A1 (es) Compuestos y usos de estos
AR127470A1 (es) Inhibidores de lrrk2
MX2025010799A (es) Inhibidores de acilsulfonamida para lisina acetiltransferasa 6a (kat6a)
CO2025002057A2 (es) Inhibidores de inflamasoma nlrp3
UY40587A (es) Inhibidores del inflamasoma nlrp3
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
CO2024017138A2 (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2023012039A (es) Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
MX2025008207A (es) Estereoisomero y derivado deuterado de compuesto de pirazoloquinazolina y uso
CO2024015686A2 (es) Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
MX2025009443A (es) Derivados de compuestos espiro sustituidos y su uso farmaceutico
AR134577A1 (es) Compuestos de bifenilo y fenilpiridina
MX2024013841A (es) Derivados de pirazina y usos de estos
CO2025006324A2 (es) Compuestos tricíclicos
MX2024013840A (es) Derivados de pirazina y usos de los mismos
UY38550A (es) Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados
AR122332A1 (es) Compuestos inhibidores de la autofagia de fenilaminopirimidina amida y composiciones que los comprenden